Aptinyx to Present Detailed Results from Phase 2 Painful DPN Study of NYX-2925 at American Pain Society Scientific Meeting

March 28, 2019

EVANSTON, Ill., March 28, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced an upcoming poster presentation highlighting the detailed results from a recently completed Phase 2 study of NYX-2925 for the treatment of painful diabetic peripheral neuropathy (DPN). The poster presentation will take place at the American Pain Society Scientific Meeting in Milwaukee, Wisconsin on April 4, 2019.

“While we announced in January that the study did not meet the primary endpoint in the total study population, the findings from the detailed analysis provide a strong scientific foundation for advancing the development of NYX-2925 for the treatment of chronic pain,” said Norbert Riedel, president and chief executive officer of Aptinyx. “The mechanism of NYX-2925 is particularly relevant to the central pain perception and processing that occurs as chronic pain persists, and we are very encouraged to see that those patients in the study who had DPN for a longer period of time showed a robust and clinically significant treatment benefit from NYX-2925 across multiple endpoints. Not only is this a critical finding based on our mechanism, but it also suggests the potential of NYX-2925 to address a major unmet medical need. Importantly, the detailed results from the study also inform future development of NYX-2925 in painful DPN. We look forward to presenting the detailed analysis at the APS Scientific Meeting.”

Poster Presentation Details:

Presentation Title: A Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety and Efficacy of NYX-2925 in Subjects with Painful Diabetic Peripheral Neuropathy (Poster Number: 409)
Presenter: Sarah Torri, MPH, Aptinyx
Presentation Date: April 4, 2019

About NYX-2925
NYX-2925 is a novel oral NMDA receptor modulator currently in Phase 2 clinical development for the treatment of chronic pain. In clinical studies, NYX-2925 has been shown to have activity that affects central pain processing, resulting in pain alleviation. In preclinical models of numerous neuropathic pain conditions, NYX-2925 has shown robust activity with a favorable tolerability profile. In Phase 1 and Phase 2 clinical studies, NYX-2925 has exhibited a favorable safety and tolerability profile across a wide dose range. The U.S. Food and Drug Administration has granted Fast Track designation to Aptinyx’s development of NYX-2925 for the treatment of neuropathic pain associated with DPN.

About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate – rather than block or over-activate – NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the company’s business plans and objectives, therapeutic effects of the company’s product candidates, expectations regarding the design, implementation, timing, and success of its current and planned clinical trials, expectations regarding its preclinical development activities, and expectations regarding its uses and sufficiency of capital. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the company’s product candidate development activities and planned clinical studies; the company’s ability to execute on its strategy; regulatory developments in the United States and foreign countries; as well as those risks and uncertainties set forth in the company’s most recent annual report on Form 10-K and in its other filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aptinyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Investor Contacts:
Nick Smith
Aptinyx Inc.
ir@aptinyx.com
847-871-0377

Rachel Frank
Stern Investor Relations
rachelf@sternir.com
212-362-1200

Media Contact:
Jordann Phillips
Canale Communications
jordann@canalecomm.com
619-849-6009

Source: Aptinyx Inc.

Source: Aptinyx Inc.